PM.20.034 – Exploring the beta cell ligandome for type 1 diabetes diagnostic

Route: Personalised medicine: the individual at the centre

Cluster question: 087 What causes type 1 and type 2 diabetes, how can we detect them sooner, and how can we treat them on an individual basis?

Diabetes currently affects 425 million people, with an estimated worldwide prevalence of 8%, and a further projected increase to 642 million by 2040. In type 1 diabetes, the insulin producing cells, within the pancreas, are targeted and destroyed by infiltrating immune cells leaving patients dependent on tight glucose control and daily insulin injection. In addition to a strong genetic predisposition, environmental factors, local inflammation and other forms of cellular stress are believed to trigger insulin producing cells dysfunction and to lead to the development of autoimmunity. In this process, the generation of neo-antigens, through the production and the accumulation of aberrant (or modified) proteins that escape central tolerance as occurring in cancer or virus-infected tissues, increases visibility of beta-cells to immune effector cells. Combining multidisciplinary expertise in molecular biology, virology, chemistry and immunology, we propose to extend our view on the beta-cell ligandome and transfer the tumor monitoring toolbox to set up a unique high throughput screening platform allowing the establishment of an evolved “immunogram” of T1D patients and high risk individuals. The identification of beta-cell specific (neo)autoantigens during the course of disease and the evaluation of their clinical relevance are critical for early diagnostic and to set the stage for personalized immune targeted therapies.


antigens, Beta cell, type 1 diabetes


Organisation Leiden University Medical Center (LUMC)
Name Dr. Arnaud Zaldumbide